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Epidermal growth factor reduces multiorgan
failure induced by thioacetamide
M E Caballero, J Berlanga, D Ramirez, P Lopez-Saura, R Gozalez, D N Floyd,
T Marchbank, R J Playford
Abstract
Background—Multiorgan failure is a
severe life threatening state where present
therapeutic approaches are suboptimal.
Epidermal growth factor (EGF) is a
potent stimulant of repair in in vitro and
in vivo models. We therefore examined its
potential beneficial eVect in reducing
mortality and injury induced by the
noxious agent thioacetamide (TAA).
Methods—Mice (20 per group) were fasted
overnight and received a single intraperi-
toneal dose of human recombinant EGF at
10 or 30 µg/kg or saline (control). Either 30
minutes before or after EGF, all animals
also received TAA (40 mg/kg intraperito-
neally). Twenty four hours later, surviving
animals were killed, tissues collected, and
degree of organ injury assessed.
Results—Fifty per cent (10/20) of control
animals died within the first 24 hour
period. Mortality was almost completely
prevented by the higher dose of EGF
whether given before or after TAA
(p<0.01) and was reduced by about 50%
with the lower dose of EGF. In control ani-
mals, the entire length of the jejunum and
ileum had necrosis with or without mu-
cosal denudation. In contrast, necrosis
aVected only about 10–20% of the total
length in EGF treated groups (both p<0.01
v control). Control animals showed
marked glomerular tuft collapse, intersti-
tial haemorrhage, and increased plasma
creatinine levels. These eVects were sig-
nificantly reduced in animals given EGF
(30 µg/kg; p<0.01). All groups showed
similar changes in liver histology (centri-
lobular necrosis) and alanine transami-
nase levels (10-fold increase).
Conclusions—Although EGF did not pre-
vent the hepatotoxicity associated with
TAA, it reduced mortality, renal injury,
and gastrointestinal damage. These stud-
ies provide preliminary evidence that
EGF may be a novel approach for the pre-
vention and/or treatment of multiorgan
failure.
(Gut 2001;48:34–40)
Keywords: gastrointestinal damage; nephrotoxicity;
liver injury
Multiple organ failure (MOF) is a severe life
threatening condition which usually occurs as a
result of major trauma, burns, or fulminant
infections. Whatever the initiating event, once
established, MOF has a high mortality (up to
80%).1 The pathophysiological mechanisms
underlying this condition are unclear although
important contributory factors probably in-
clude hypoxia, increased intestinal permeabil-
ity, bacterial translocation, endotoxaemia, and
uncontrolled systemic inflammatory responses
(see Nguyen and colleagues2).
Novel therapies that reduce the risk of
patients developing MOF have direct clinical
potential. Many of the patients who progress to
MOF while an inpatient can be identified at an
early stage, often at the time of admission,
based on the severity of initial injury, for exam-
ple, percentage of skin surface area aVected in
burns patients. There is therefore a potential
therapeutic window where agents such as
epidermal growth factor (EGF) could be
administered prior to the development of the
full MOF syndrome.
Thioacetamide (TAA) has been used exten-
sively as an hepatotoxin to establish animal
models of acute and chronic liver injury.3 4 Its
injurious eVects have been attributed, in part,
to the biotransformation of TAA to the TAA
sulphone and sulphoxide forms which react
extensively with proteins, resulting in their
denaturation.5 6 Although less well studied,
administration of TAA can also result in dam-
age to the kidney (particularly the proximal
tubule7) and gastrointestinal tract,8 suggesting
that administration of TAA might be a useful
model of multiorgan failure.
EGF is a 53 amino acid peptide produced by
the salivary glands and Brunner’s glands of the
duodenum. It is a potent stimulant of prolifera-
tion and healing of the gastrointestinal tract,
acting as a cytoprotective agent, “stabilising”
cells against noxious agents such as indometh-
acin.9 In addition, we have recently shown that
EGF can prevent hepatic injury induced by
carbon tetrachloride.10 There is therefore inter-
est in its potential clinical value for the
treatment of human gastrointestinal and he-
patic disease. We now report our studies exam-
ining whether EGF can influence the degree of
renal, hepatic, and gastrointestinal injury
caused by the noxious agent TAA.
Materials and methods
ANIMALS
Adult male OF-1 male mice (20–22 g) were
housed individually in wire bottomed cages
and allowed free access to water and commer-
Abbreviations used in this paper: EGF; epidermal
growth factor; hrEGF, human recombinant EGF;
TAA; thioacetamide; MOF, multiple organ failure;
ALAT, alanine aminotransferase.
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cial chow. Animals were acclimatised for seven
days before experiments, which were per-
formed according to local regulatory guide-
lines.
CHEMICALS
Human recombinant (hr) EGF, expressed in
Saccharomyces cerevisiae, was purchased from
HeberBiotc SA (Havana, Cuba). Prior to
administration, hrEGF was diluted in 0.9%
saline and sterilised via passage through a 0.22
µm filter. TAA was obtained from Sigma
Chemical Co. (St Louis, Missouri, USA) and
diluted in saline. All solutions were freshly pre-
pared before each experiment.
BIOCHEMICAL ASSAYS
Serum levels of alanine aminotransferase
(ALAT) were measured colorimetrically,11 ac-
cording to the supplier’s instructions (HoVman
LaRoche, Basel, Switzerland). Serum levels of
creatinine were measured according to the
manufacturer’s instructions (Reactivos SPIN-
REACT SA, Barcelona, Spain).
EXPERIMENTAL PROTOCOLS
Mice were fasted for 16 hours before com-
mencement of all experiments
Preliminary studies
A series of preliminary experiments were
performed examining the eVect on survival of
various doses of TAA given alone. Groups of
10 mice were given 10, 20, 40, or 60 mg/kg of
TAA (single intraperitoneal injection) and were
then observed for 48 hours. Mortality rates
over this period were 10, 20, 60, and 100% for
animals given 10, 20, 40, and 60 mg/kg of TAA,
respectively, with virtually all deaths occurring
20–21 hours after administration of TAA. The
dose of 40 mg/kg was chosen for subsequent
studies as this was approximately the LD50.
EVect of pretreatment with EGF on TAA toxicity
For logistical reasons, two independent experi-
ments were performed on two separate occa-
sions. In each experiment, mice (10 per group)
were assigned randomly to receive saline or
hrEGF (10 or 30 µg/kg intraperitoneally) 30
minutes before receiving TAA (40 mg/kg intra-
peritoneally in a volume of 1 ml). After 24
hours, surviving animals were anaesthetised
lightly with diethylether and blood collected via
cardiac puncture. Animals were then killed by
cervical dislocation and autopsies performed.
Stomachs were collected and inflated with 3 ml
of 10% buVered formalin. They were subse-
quently opened along the greater curvature,
rinsed in saline, and examined for mucosal
damage using a dissecting microscope. The
small intestinal tract was dissected free, flushed
with 2 ml of normal saline, weighed, opened
along its length using dissecting forceps, and
macroscopically inspected. The proximal 5 cm
of the small intestine (“duodenum”) was
collected for analysis and a further five (2 cm)
equi-spaced segments were then taken from the
remaining length of the small intestine, fixed in
buVered formalin, and subsequently processed
for morphological assessment (see below). The
kidneys, liver, large intestine, heart, lungs,
spleen, and pancreas were also collected and
processed for histological assessment.
A further six mice, housed under identical
circumstances, were not given TAA or EGF
but were treated in an identical fashion to
determine locally validated “normal” values.
MICROSCOPIC ANALYSES
All histological and morphometric determina-
tions were performed in a blinded fashion.
Computer based image analysis was used to
quantify small intestinal and hepatic damage.
Briefly, microscopic images were captured
using a Sony DXC-107 camera, displayed on
an IBM computer via a VideoBlaster SE-100
frame grabber card. A 4× objective lens was
used for assessment of intestinal injury and a
25× lens for hepatic assessment.
For intestinal injury, each microscopic field
extended over 1500 µm and included approxi-
mately 25 villi and vertically sectioned crypts.
The entire length of the tissue samples was
analysed using the DIGIPAT morphometric
image processing package (EICISOFT Calle
24 No. 408, Vedado, Havana, Cuba). The total
length of severely damaged mucosa, defined as
regions of frank necrosis, was then determined
and expressed as a percentage of the whole
length of tissue examined.
Hepatic tissues were treated in a similar
fashion with the images being captured and
quantitated using the same equipment and
software as that used for intestinal tissue. The
total area of injury in each fragment was deter-
mined in a standardised tissue area of 40 mm2,
by measuring and adding the size of the
individual pericentral pale foci.
For renal tissue, the number of damaged
glomeruli and haemorrhagic foci per field were
determined using a 10× objective lens.
EVect of EGF on TAA toxicity when administered
after TAA
To examine the potential value of EGF when
given after TAA, two separate independent
experiments were performed using identical
protocols with n=10 per group on each
occasion. The protocol used was as described
above except that EGF was given 30 minutes
after TAA instead of 30 minutes before. For
these studies, we also used a diVerent set of
parameters to measure gut injury to show that
the apparent alteration in injury was not
dependent on using a particular assay method.
At the end of the study, the small intestine was
flushed with 2 ml of ice cold saline and the fluid
collected for subsequent haemoglobin assay
using a commercial kit (Reactivos SPINRE-
ACT SA, Barcelona, Spain) with the cyan-
omethahaemoglobin method. The small intes-
tine was opened along its length, washed with
further cold saline, blotted with paper, and
weighed. It was then homogenised in phos-
phate buVered saline and aliquots taken to
determine total protein using the Lowry
method. Separate aliquots were used to deter-
mine total DNA content using a commercial
kit (GeneQuant, Pharacia). Briefly, this was
achieved by digesting the tissue homogenate
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for four hours at 55°C in extraction buVer con-
taining 1 M Tris pH 8, 0.5 M EDTA, 20%
SDS, and 20 mg proteinase K. This was
followed by three cycles of phenol/chloroform
extraction and the DNA precipitated with
ethanol. The pellet was dried and resuspended
in 100 µl of TE for subsequent spectrophomet-
ric quantitation at 260 nm. Results are
expressed as the mean of three reading. Blood
samples were collected by cardiac puncture for
ALAT and creatinine assays.
STATISTICS
Data from the experiments using the same
protocols on the two separate occasions were
virtually identical, confirming the reproduc-
ibility of our findings. To demonstrate this
reproducibility, we have shown the results for
mortality data both as separate and cumulative
results (tables 1, 2). Subsequent analyses of
data for organ damage from the two occasions
have been pooled for statistical comparisons.
Mortality data were compared using a ÷2 test.
As the data from biochemical and histological
analyses were not normally distributed, data
are presented as medians and interquartile
ranges and statistical analyses used the non-
parametric Mann-Whitney U test.
Results
MORTALITY
In animals who died within the initial 24 hour
observation period, deterioration in general
condition was observed 16 hours after TAA
administration with progressive lethargy, pilo-
erection, and prostration. All deaths occurred
20–21 hours after TAA injection. For the study
involving animals that received EGF prior to
TAA, mortality was 50% in control animals,
20% in animals that had received the lower
dose of EGF, and 0% in animals given the
higher dose of EGF (table 1). EGF showed a
similar protective eVect in animals when
administered after TAA (table 2). Postmortem
examination showed large amounts of intra-
luminal bleeding in the small intestine with
histological changes similar to those found in
animals that survived. Morphometric analyses
of small intestinal tissue were not performed in
animals that died in this initial 24 hour period
as postmortem changes may have influenced
the results.
MACROSCOPIC OBSERVATIONS OF SURVIVING
ANIMALS AT AUTOPSY
Control animals showed increased friability of
the small intestine and liver. Many of the
animals also showed evidence of intraluminal
Table 1 Twenty four hour survival values for rats given
thioacetamide (TAA) (40 mg/kg) with or without
epidermal growth factor (EGF) 30 minutes prior to
administration of TAA. Ten mice were entered into each
group on both experimental occasions
Experiment TAA alone
TAA+EGF
(10 µg/kg)
TAA+EGF
(30 µg/kg)
1 4/10 (40%) 8/10 (80%) 10/10 (100%)
2 6/10 (60%) 8/10 (80%) 10/10 (100%)
Pooled data 10/20 (50%) 16/20 (80%) 20/20 (100%)*
*p<0.05 v TAA alone.
Table 2 Twenty four hour survival values for rats given
thioacetamide (TAA) with or without epidermal growth
factor (EGF) 30 minutes after administration of TAA. Ten
mice were entered into each group on both experimental
occasions
Experiment TAA alone
TAA+EGF
(10 µg/kg)
TAA+EGF
(30 µg/kg)
1 4/10 (40%) 7/10 (70%) 9/10 (90%)
2 5/10 (50%) 8/10 (80%) 10/10 (100%)
Pooled data 9/20 (45%) 15/20 (75%) 19/20 (95%)*
*p<0.05 v TAA alone.
Figure 1 Thioacetamide (TAA) induced small intestinal injury. (A) Twenty four hours after administration of TAA (40
mg/kg) to mice, the normal villus structure of the jejunum and ileum is lost and marked necrosis is seen within the
remaining mucosa. (B) Administration of epidermal growth factor (EGF, 30 µg/kg), 30 minutes prior to TAA,markedly
preserved small intestinal architecture. Similar preservation was seen when a dose of 10 µg/kg of EGF was used (not
shown). Tissues were stained with haematoxylin and eosin. Original magnification ×10. Bar=100 µm.
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bleeding into the small intestine. Similar
changes were seen in the EGF treated animals
although they were considered to be less severe
qualitatively and this was confirmed quantita-
tively in animals given EGF after TAA (see
below). Heart, lungs, spleen, pancreas, and
kidneys appeared macroscopically normal.
FURTHER RESULTS FROM STUDIES WHERE EGF
WAS GIVEN BEFORE TAA
Microscopic assessment
The major histological changes were present in
the small intestine, liver, and kidney.
Intestine. Control animals had minimal histo-
logical changes in the duodenum. In contrast,
the entire length of the jejunum and ileum
showed extensive mucosal necrosis, usually
associated with denudation (fig 1A). These
changes were significantly reduced in both high
and low dose EGF treated animals (fig 1B).
Quantitative assessment showed that animals
given TAA without EGF had mucosal necrosis
of the jejunum and ileum aVecting 100% of its
length. In contrast, both doses of EGF signifi-
cantly reduced the length of small intestinal
tissue showing necrosis (both p<0.05 v TAA
treated animals not given EGF; table 3). The
large intestine was histologically normal in all
groups.
Liver. Centrolobular necrosis, occasionally
associated with haemorrhagic foci, were seen in
all three groups (fig 2), often with some degree
of inflammatory infiltration. Administration of
TAA caused serum ALAT levels to increase by
about 10-fold (p<0.01) (table 3). Pretreatment
with EGF did not aVect the amount of hepatic
injury caused in response to administration of
TAA, as assessed using histology or the
increase in transaminase levels (table 3).
Kidneys. Control animals showed extensive
collapse of the glomerular tufts (fig 3A). Minor
degenerative acute changes were also found in
the epithelial cells of the tubular system and
haemorrhagic areas were also present in the
medulla (fig 3B). These changes were reduced
in both high and low dose EGF treated animals
(fig 3C). Quantitation, as assessed by the
number of collapsed glomerular tufts and
haemorrhagic foci seen during microscopic
examination, and changes in plasma creatinine
levels, supported this finding of a protective
eVect of EGF. For all of these parameters,
administration of either the high or low dose of
EGF resulted in a significant reduction in the
amount of injury by about 70–80% (table 3).
FURTHER RESULTS FROM STUDIES WHERE EGF
WAS GIVEN AFTER TAA
TAA alone caused a marked reduction in DNA
and protein content expressed on a per gram
wet weight basis (fig 4). TAA also caused a
marked increase in luminal haemoglobin. As in
the protocol involving EGF prior to TAA,
plasma ALAT and creatinine increased. Ad-
ministration of EGF after TAA reduced most
of the changes caused by TAA (fig 4); luminal
haemoglobin and plasma creatinine were
significantly lower than in animals given TAA
alone, and mucosal DNA and protein content
were significantly higher. EGF did not, how-
ever, reverse the rise in ALAT caused by TAA.
Discussion
We examined the eVect of administration of
high dose thioacetamide on multiple organ
systems and determined the influence of EGF
on the degree of injury sustained. Administra-
tion of TAA (40 mg/kg intraperitoneally) was
associated with 50% mortality with the major
sites of injury being the small intestine, liver,
and to a lesser extent the kidneys. Administra-
tion of EGF either before or 30 minutes after
TAA markedly reduced the mortality rate,
intestinal injury, and renal damage in a dose
dependent manner. However, administration
of EGF had little eVect on the degree of hepatic
injury sustained, as assessed histologically and
biochemically.
Administration of TAA is a well established
method of inducing hepatic injury.3 4 Its toxic-
Table 3 EVect of pretreatment with epidermal growth factor (EGF, 10 or 30 µg/kg) on thioacetamide (TAA) damaged organ systems. Control animals
did not receive TAA or EGF.All of the reported parameters for the TAA treated groups (TAA alone and TAA+EGF) were significantly greater than those
of the control
Treatment
Organ Parameter (units) Control TAA TAA + EGF 10 TAA + EGF 30
Jejunum + ileum Length showing necrosis (% total) 0 (0–0) 100 (100–100) 20.5 (12.8–36.4)* 10.1 (8.5–15.8)*
Liver Area of necrosis (%total) 0 (0–0) 23.5 (20.5–26.5) 25 (20.5–29.5) 21.5 (20–27)
Liver Serum ALAT (U/1) 157 (150–172) 1550 (1310–1790) 1510 (1165–1660) 1710 (1640–1760)
Kidney Serum creatinine (mg/1) 26 (8.9–26) 59 (44–74) 49.6 (40.2–55.2) 44 (36.5–51.5)*
Kidney No collapsed glomerular tufts (per 10 high powered fields) 0 (0–0) 17.1 (12.1–20)* 8.6 (5.7–13.6)*
Kidney No haemorrhagic foci (per 10 high powered fields) 0 (0–0) 2.1 (1.1–3.9)* 7.1 (5.7–11.4)*
Results are median (interquartile range).
*p<0.05 v values in animals given TAA without EGF.
Figure 2 Thioacetamide (TAA) induced hepatic injury. TAA treated animals showed
marked hepatic injury, mainly centrilobular necrosis with occasional haemorrhagic foci. The
histological appearance was similar in all treatment groups. Tissues were stained with
haematoxylin and eosin. Original magnification ×20. Bar=50 µm.
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ity is probably related to biotransformation of
TAA to the TAA sulphone and sulphoxide
forms which react extensively with proteins,
forming acetylimidolysine derivatives, resulting
in their denaturation and charge modifica-
tion.5 6 Multiple protein systems have been
shown to be injured, including those present in
the endoplasmic reticulum, those involved in
mitochondrial respiration, and stress response
proteins such as the heat shock protein
family.6 12 13 TAA may also injure cells by acting
as a generator of free radicals,14 resulting in
lipid peroxidation. Whatever the molecular
mechanisms involved, administration of TAA
results in increased apoptosis and necrosis,
with necrosis being predominant when high
doses of TAA are used.15 In the present series of
studies, histological examination of intestinal
tissue showed that necrotic changes were
prominent throughout the small intestine.
Necrosis was therefore likely to be the major
final pathway of intestinal injury under these
particular circumstances. Some degree of
apoptosis does take place in this model,
however, as shown by the presence of low lev-
els of DNA laddering when collected intestinal
residual DNA is run on agarose gels (CIGB,
personal communication). Further examina-
tion of this process could potentially follow
changes in apoptosis related enzymes such as
caspases but would be complicated by the fact
that little viable mucosal tissue is left in a field
containing high levels of necrotic tissue.
The hepatic changes seen in the present
study (centrilobular necrosis and raised
transaminase levels) have been described
previously.3 4 It has also been noted that TAA
can injure other organ systems, including the
intestine and kidneys.7 8 Ortega et al found that
chronic oral administration of TAA to rats in
their drinking water caused enlargement of
intercellular spaces of the jejunum and ileum
with lymphocytic infiltration.8 Much more
extensive changes were found in our studies
using mice where virtually complete necrosis of
the mucosa was seen. This diVerence in toxic-
ity probably relates to the dosage used (40
mg/kg in the present study versus about 25
mg/kg) but may also relate to diVerences in the
route of administration and species studied. In
contrast with the study of Ortega et al, we
examined the entire small intestine and found
that the proximal gut (duodenum) was virtu-
ally unaVected by administration of TAA. The
reason why the proximal bowel remained intact
is unclear but may be due to enterohepatic cir-
culation of toxic metabolites of TAA (which
would result in relative sparing of the duode-
num proximal to the ampulla), the requirement
for pancreatic proteases to injure the intestine,
or that the splanchnic blood flow to the duode-
num was better preserved.
The predominant histological changes seen
within the kidney were of tuft collapse with
minor degenerative changes in the proximal
tubule. Part of the explanation for this tuft col-
lapse could be due to hypoperfusion induced
by blood loss into the bowel lumen. Both the
tuft collapse and tubular injury were prevented
by administration of EGF. It is noteworthy that
for both the intestinal and renal changes, TAA
induced histological damage has been likened
to that seen following ischaemia/reperfusion
events.16 17 In addition to the molecular mecha-
nisms described above, TAA may therefore also
cause injury by inducing vasoconstriction or by
Figure 3 Thioacetamide (TAA) induced renal injury. Tissues were stained with
haematoxylin and eosin. The renal tissue of TAA treated animals showed extensive collapse
of the glomerular tufts.. Original magnification ×10. (B) Higher power photomicrograph of
the same tissue demonstrating that only minor degenerative acute changes in the epithelial
cells of the tubular system were seen. Original magnification ×20. Bar=50 µm. (C)
Pretreatment with EGF reduced the renal changes caused by TAA.Original magnification
×20. Bar=50 µm.
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interference with other key pathways involved
in cellular respiration.
The major sources of EGF production are
the salivary glands, Brunner’s glands of the
duodenum, and the kidney. Many studies have
shown EGF to be a potent stimulant of growth
for various cell types in vitro18 and in vivo19 and
that it acts as a cytoprotective agent against
gastrointestinal injury caused by a variety of
noxious agents such as non-steroidal anti-
inflammatory drug induced gastric injury9 20
and trinitrobenzenesulphonic acid induced
colitis.21 In addition, we have shown recently
that exogenous EGF reduced carbon tetrachlo-
ride mediated hepatic damage,10 suggesting it
might be of value in the prevention and
treatment of hepatic injury. There is relatively
little information, however, regarding its value
for preventing/treating injury sustained in mul-
tiple organ systems, such as occurs during
MOF.
The biochemical and histological data de-
rived from these studies showed that EGF can
markedly reduce intestinal and renal injury
caused by TAA in a dose dependent fashion.
The mechanism(s) by which EGF exerted
these eVects is, however, unclear. EGF influ-
ences multiple systems which might be impor-
tant in mediating these eVects, including
upregulation of prostaglandin20 and mucus22
production, increasing mesenteric blood
flow,23 24 upregulation of superoxide dismutase
(thereby reducing free radical induced toxic-
ity),25 and influencing stress associated protein
kinases.26 Interestingly, EGF did not appear to
influence the degree of hepatic injury yet
markedly diminished mortality. It is therefore
likely that the severe intestinal damage with
intraluminal haemorrhage, caused by TAA,
was the major factor that resulted in death of
the animals.
Figure 4 EVect of epidermal growth factor (EGF) given 30 minutes after thioacetamide (TAA) on multiple organ
systems. EGF reduced luminal bleeding (A), and the reduction in wet weight (B), DNA (C), and protein content (D) of
the gut caused by TAA. The rise in plasma creatinine caused by TAA was also reduced by administration of EGF (E)
although it did not influence the rise in serum alanine aminotransferase (ALAT) (F). *p<0.05, **p<0.01 compared with
animals given TAA alone.
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Clinical trials of EGF are presently under-
way for the treatment of ulcerative conditions
of the bowel, such as necrotising enterocolitis.27
Our studies provide preliminary evidence that
EGF may also be of benefit in MOF where
increased gut permeability is thought to be an
important component in its aetiology.2 MOF is
a severe life threatening condition which
usually occurs as a result of major trauma,
burns, or fulminant infection.1 The patho-
physiological mechanisms underlying MOF
are unclear although important contributory
factors probably include hypoxia, increased
intestinal permeability, bacterial translocation,
endotoxaemia, and uncontrolled systemic in-
flammatory responses.2 Whatever the initiating
event, once established, MOF has a high mor-
tality.1 Two of the most popular animal models
used to induce MOF are administration of
zymosan,28 which causes MOF by inducing
pancreatic damage, and enterotoxin adminis-
tration, which results in MOF via multiple
mechanisms, including cardiovascular col-
lapse.29 The present studies suggest TAA
induced injury provides a complimentary
model which has its predominant initial toxic
eVects on the liver and small intestinal mucosa.
Novel therapies that can reduce the risk of
patients developing MOF have direct clinical
potential. Many of the patients who progress to
MOF while an inpatient can be identified at an
early stage, often at the time of admission,
based on the severity of initial injury, for exam-
ple, percentage of skin surface area aVected in
burns patients.1 2 There is therefore a potential
“therapeutic window” where agents such as
EGF could be administered prior to the devel-
opment of the full MOF syndrome. Further
research examining the potential benefit of
EGF itself or other EGF receptor ligands, such
as transforming growth factor á and am-
phiregulin, in the prevention of MOF and in
the treatment of MOF once fully established,
appear warranted.
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